RSS-Feed abonnieren
DOI: 10.1055/s-2007-959305
© Georg Thieme Verlag KG Stuttgart · New York
Hormontherapie des Prostatakarzinoms - Übersicht und aktueller Stand
Hormonal treatment of cancer of the prostate: review and present statusPublikationsverlauf
eingereicht: 11.9.2006
akzeptiert: 30.11.2006
Publikationsdatum:
18. Januar 2007 (online)

Zusammenfassung
Das Prostatakarzinom (PC) ist in der westlichen Welt der häufigste bösartige Tumor des Mannes. Durch die Einführung des PSA-Screenings wird das es zunehmend in potenziell kurablen Tumorstadien diagnostiziert. Dennoch kommt es nach kurativer Therapie innerhalb von 15 Jahren in bis zu 50 % zu einem erneuten Anstieg des PSA-Wertes und im Median nach weiteren 8 Jahren in 34 % zu einer Metastasenbildung. Beim systemischen Rezidiv ist die Hormontherapie die wichtigste palliative Maßnahme. Sie wird ebenfalls als Primärtherapie und in Kombination mit anderen Therapieformen eingesetzt. Die verschiedenen Methoden der Kastration (chirurgisch, medikamentös) sind vom Gesamtüberleben her vergleichbar. Die heutzutage für die medikamentöse Kastration eingesetzten LH-RH-Agonisten haben typische Nebenwirkungen in Form von Impotenz (69 %), Hitzewallungen (56,5 %), Gynäkomastie (24,9 %) und Osteoporose. Initial führen LH RH-Agonisten zu einem passageren Serum-Testosteronanstieg (Flare-Phänomen). Dies kann durch LH-RH-Antagonisten vermieden werden, die in Europa noch nicht zugelassen ist. Eine weitere Medikamentengruppe sind die Antiandrogene, die ein günstigeres Nebenwirkungsprofil als die Formen der Kastration besitzen. Das Antiandrogen Bicalutamid führt beim lokal fortgeschrittenen PC, adjuvant zur Radiatio verabreicht, zu einer Überlebensverlängerung, nicht aber bei der Gabe nach radikaler Prostatektomie oder bei Versagen einer „Watchful-waiting”-Strategie. Beim metastasierten PC sind Antiandrogene der Kastration im Gesamtüberleben statistisch signifikant unterlegen. Die Bedeutung der maximalen Androgenblockade (Kombination aus Kastration und Antiandrogen) wird anhaltend kontrovers diskutiert. Sie bietet beim metastasierten PC einen geringen Überlebensvorteil von wenigen Monaten bei deutlicher Zunahme der Nebenwirkungen.
Summary
Prostatic cancer (PC) heads the list of malignant tumors in the male. Resulting from the introduction of prostatic-specific antigen (PSA) screening there has been a shift towards potentially curable tumor stages. However, after curative treatment a rise in PSA has been noted in up to 50% of cases within 15 years. Metastases are then reported in up to 34% within the subsequent eight years. Hormonal therapy represents the most important palliative measure in metastatic PC and is also used in primary, adjuvant and neo-adjuvant hormonal treatment. The different methods of castration (orchidectomy, medical castration) are equivalent in respect of overall survival. The side effects of agonists of luteinizing-hormone-releasing hormone (LHRH) are impotence (69%), hot flushes (56.5%), gynecomastia (24.9%) and osteoporosis and may initially cause a transitory increase in serum testosterone (flare phenomenon). This can be counteracted by an LHRH antagonist (not available in Europe). Anti-androgens do not lead to testosterone suppression and have a more favorable profile of side effects. Bicalutamide significantly improves overall survival rate in patients receiving radiotherapy. However, overall survival rate is not improved in patients after radical prostatectomy or under watchful waiting. Bicalutamide alone is less efficacious than castration in patients with metastases. The use of maximal androgen blockade (combination of castration and anti-androgen) remains controversial. It seems to produce a modest overall and cancer-specific increase in survival rate but is associated with increased adverse events and a reduced quality of life.
Schlüsselwörter
Prostatakarzinom - Hormontherapie - Kastration - maximale Androgenblockade - Flare - Phänomen
Key words
prostate cancer - hormone therapy - castration - maximal androgen blockade - flare phenomenon
Literatur
- 1
Bolla M, Collette L, Blank L. et al .
Long-term results with immediate androgen suppression and external irradiation in
patients with locally advanced prostate cancer (an EORTC study): a phase III randomised
trial.
Lancet.
2002;
360
103-106
MissingFormLabel
- 2
Bubley G J.
Is the flare phenomenon clinically significant?.
Urology.
2001;
58
5-9
MissingFormLabel
- 3
Byar D P, Corle D K.
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative
Urological Research Group studies.
NCI Monogr.
1988;
7
165-170
MissingFormLabel
- 4
Catalona W J, Smith D S, Ratliff T L. et al .
Measurement of prostate-specific antigen in serum as a screening test for prostate
cancer.
N Engl J Med.
1991;
324
1156-1161
MissingFormLabel
- 5
Culig Z, Hobisch A, Bartsch G. et al .
Androgen receptor - an update of mechanisms of action in prostate cancer.
Urol Res.
2000;
28
211-219
MissingFormLabel
- 6
Denis L J, Carnelro de Moura J L, Bono A. et al .
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial
(30853): EORTC GU Group and EORTC Data Center.
Urology.
1993;
42
119-129
MissingFormLabel
- 7
Eisenberger M A, Blumenstein B A, Crawford E D. et al .
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
N Engl J Med.
1998;
339
1036-1042
MissingFormLabel
- 8
Grossfeld G D, Chang J J, Broering J M. et al .
Under staging and under grading in a contemporary series of patients undergoing radical
prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research
Endeavor database.
J Urol.
2001;
165
851-856
MissingFormLabel
- 9
Huggins C B, Hodges C V.
Studies on prostate cancer: The effects of castration, of estrogen and androgen injection
on serum phosphatases in metastatic carcinoma of the prostate.
Cancer Res.
1941;
1
293-297
MissingFormLabel
- 10 Hunter J. The works of John Hunter F. R. S. With Notes. London: Longman Edited by J. F. Palmer 1837
MissingFormLabel
- 11
Iversen P.
Quality of life issues relating to endocrine treatment options.
Eur Urol.
1999;
(Suppl 2)
36
20-26
MissingFormLabel
- 12
Iversen P, Tyrrell C J, Kaisary A V. et al .
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with
previously untreated nonmetastatic prostate cancer: results from two multicenter randomized
trials at a median follow-up of 4 years.
Urology.
1998;
51
389-396
MissingFormLabel
- 13
Iversen P, Tyrrell C J, Kaisary A V. et al .
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally
advanced prostate cancer: 6.3 years of followup.
J Urol.
2000;
164
1579-1582
MissingFormLabel
- 14
Klotz L, McNeill I, Fleshner N.
A phase 1 - 2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate
carcinoma.
J Urol.
1999;
161
169-172
MissingFormLabel
- 15 Krebs in Deutschland. 5. überarbeitete, aktualisierte Ausgabe Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. und das RKI.
Saarbrücken 2006
MissingFormLabel
- 16
Mc Ieod D G, Iversen P, See W A. et al .
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
BJU Int.
2006;
97
247-254
MissingFormLabel
- 17
Miyamoto H, Yeh S, Lardy H. et al .
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate
cancer cells.
Proc Natl Acad Sci U S A.
1998;
95
11083-11088
MissingFormLabel
- 18
Moffat L E.
Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced
prostate cancer.
Eur Urol.
1990;
18
(Suppl 3)
26-27
MissingFormLabel
- 19
Nyman C R, Andersen J T, Lodding P. et al .
The patient’s choice of androgen-deprivation therapy in locally advanced prostate
cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
BJU Int.
2005;
96
1014-1018
MissingFormLabel
- 20
Paquette E L, Sun L, Paquette L R. et al .
Improved prostate cancer-specific survival and other disease parameters: impact of
prostate-specific antigen testing.
Urology.
2002;
60
756-759
MissingFormLabel
- 21 Pelikan E. Gerichtlich-medicinische Untersuchungen uber Das Skopzenthum in Russland, nebst historischen
Notizen. Giessen: Ricker 1876
MissingFormLabel
- 22
Potosky A L, Knopf K, Clegg L X. et al .
Quality-of-life outcomes after primary androgen deprivation therapy: results from
the Prostate Cancer Outcomes Study.
J Clin Oncol.
2001;
19
3750-3757
MissingFormLabel
- 23
Pound C R, Partin A W, Eisenberger M A. et al .
Natural history of progression after PSA elevation following radical prostatectomy.
JAMA.
1999;
281
1591-1597
MissingFormLabel
- 24
Prostate Cancer Trialists’ Collaborative Group .
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised
trials.
Lancet.
2000;
355
1491-1498
MissingFormLabel
- 25
Radlmaier A, Bormacher K, Neumann F.
Hot flushes: mechanism and prevention.
Prog Clin Biol Res.
1990;
359
131-140
MissingFormLabel
- 26
Riba L W.
Subcapsular castration for carcinoma of prostate.
J Urol.
1942;
48
384-387
MissingFormLabel
- 27
Rohde V, Wellmann A, Fogt F. et al .
Economical data and advanced prostate carcinoma: do we need new guidelines for decision
making?.
Oncol Rep.
2002;
9
1185-1188
MissingFormLabel
- 28
Scherr D S, Pitts W R.
The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation
therapy without estrogen deprivation in the treatment of prostate cancer.
J Urol.
2003;
170
1703-1708
MissingFormLabel
- 29
Schroder F H, Collette L, de Reijke T M. et al .
Prostate cancer treated by anti - androgens? is sexual function preserved: EORTC Genitourinary
Group. European Organization for Research and Treatment of Cancer.
Br J Cancer.
2000;
82
283-290
MissingFormLabel
- 30
Seidenfeld J, Samson D J, Hasselblad V. et al .
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic
review and meta - analysis.
Ann Intern Med.
2000;
132
566-577
MissingFormLabel
- 31
The Veterans Administration Co-operative Urological Research Group .
Treatment and survival of patients with cancer of the prostate.
Surg Gynecol Obstet.
1967;
124
1011-1017
MissingFormLabel
- 32
Trachtenberg J, Gittleman M, Steidle C. et al .
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide
plus daily antiandrogen in men with prostate cancer.
J Urol.
2002;
167
1670-1674
MissingFormLabel
- 33
Tsai M J, O’Malley B W.
Molecular mechanisms of action of steroid/thyroid receptor superfamily members.
Annu Rev Biochem.
1994;
63
451-486
MissingFormLabel
- 34
Tyrrell C J, Kaisary A V, Iversen P. et al .
A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration
in the treatment of metastatic and locally advanced prostate cancer.
Eur Urol.
1998;
33
447-456
MissingFormLabel
- 35
Wang M C, Valenzuela L A, Murphy G P. et al .
Purification of a human prostate specific antigen.
Invest Urol.
1979;
17
159-163
MissingFormLabel
- 36
Weckermann D, Harzmann R.
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
Eur Urol.
2004;
46
279-283
MissingFormLabel
- 37
White W J.
Surgical of the hypertrophied prostate.
Ann Surg.
1893;
17
70-75
MissingFormLabel
- 38
Widmark A, Fossa S D, Lundmo P. et al .
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation
of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3.
Urology.
2003;
61
145-151
MissingFormLabel
- 39
Wirth M P, See W A, Mcleod D G. et al .
Bicalutamide 150 mg in addition to standard care in patients with localized or locally
advanced prostate cancer: results from the second analysis of the early prostate cancer
program at median followup of 5.4 years.
J Urol.
2004;
172
1865-1870
MissingFormLabel
- 40
Zhang X Z, Donovan M P, Williams B T. et al .
Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate
cancer.
Urology.
1996;
47
402-404
MissingFormLabel
Dr. med. Roman Ganzer
Klinik und Poliklinik für Urologie, Universität Regensburg, Krankenhaus St. Josef
Landshuter Straße 65
93053 Regensburg
Telefon: 0941/7823533
Fax: 0941/7823515
eMail: roman.ganzer@gmx.de